Andre Heeres

Andre has a broad chemical expertise and joined several companies within The Netherlands before moving to Syncom. Within his position as Project leader/manager he was responsible for the design and in vitro and in vivo optimization in several hit-to-lead programs for neurodegenerative diseases, atrial fibrillation and diabetes. Furthermore, he has lots of experience in the modification of (chiral) building blocks (carbohydrates, amino acids, steroids) towards high-value compounds for the pharmaceutical and food industry, resulting a several patent applications. Currently he is involved in several collaborations with the UMCG and RUG in early stage drug discovery and the bio-based economy.